Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027

Reuters

2025/09/30

Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027

**Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2571363561"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2571363561\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2571363561?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-30 05:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2571363561","market":"nz","top_or_hot":-1,"title":"Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-09-30 05:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - <a href=\"https://laohu8.com/S/STRO\">Sutro Biopharma Inc</a>. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"STRO","symbol_name":"Sutro Biopharma Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250929:nNDL5Fy3Tn:1","article_id":"2571363561","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2571363561","pubTimestamp":1759179770,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"**Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. , a biotechnology company specializing in antibody drug conjugates  for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"STRO":"Sutro Biopharma Inc","BK4139":"生物科技"},"translate_title":"Sutro Biopharma宣布重大重组，裁员三分之一，以将现金跑道延长至2027年","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"STRO":0.9},"content_text":"Sutro Biopharma Announces Major Restructuring, Cuts Workforce by One-Third to Extend Cash Runway Through 2027\n    \n\n        **Sutro Biopharma Announces Corporate Restructuring to Extend Cash Runway** SOUTH SAN FRANCISCO, Calif., September 29, 2025 - Sutro Biopharma Inc. (NASDAQ: STRO), a biotechnology company specializing in antibody drug conjugates (ADCs) for cancer treatment, has announced a major organizational restructuring. The company will reduce its workforce by approximately one-third to focus resources on advancing its three key ADC programs and research collaborations. This move, combined with anticipated near-term milestone payments, is expected to extend the company's financial runway into at least mid-2027. Sutro plans to advance its next-generation Tissue Factor-targeting exatecan ADC, STRO-004, into clinical trials this year, with initial data expected in 2026. CEO Jane Chung said the changes will help the company reach critical development milestones and deliver value to patients and shareholders.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sutro Biopharma Inc. published the original content used to generate this news brief on September 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}